论文部分内容阅读
目的：观察重组人血管内皮抑制素（恩度）胸腔内注射治疗非小细胞肺癌合并恶性胸腔积液的疗效和安全性。方法：25例经病理学和细胞学检查确诊非小细胞肺癌合并恶性胸腔积液患者，给予胸腔内注射重组人血管内皮抑制素（恩度），具体方法为：恩度30mg/次，q2d ×3(d1、d3、d5)，连续3次为1疗程，最多可连续接受2疗程治疗。参照WHO关于癌性胸腔积液疗效判断标准统一评估疗效，结果：25例患者共完成40个疗程，有效率60%。全组患者耐受良好，无严重不良反应。结论：重组人血管内皮抑制素胸腔内注射治疗非小细胞肺癌合并恶性胸腔积液安全有效，有待深入研究。“,”Objective To observe the efficacy and safety of intrapleural injection recombinant human endostatin in non-small cell lung cancer with malignant pleural effusion.Methods 25 patients were diagnosed non-small cell lung cancer with malignant pleural effusion through pathology and cytology,All patient were given cavity infusion recombinant human endostatin. The dosage wase taken as follow:endostatin 30 mg per time on d1 d3 d5,three consecutive cavity infusion was a cycle, and all patients were treated no more than 2 cycles. The efficacy was evaluated strictly according to WHO criteria.Results 25 patients were completed 40 cycle,objective response rate was 60%. All patients were of good tolerance as a whole and no severe side effects happened.Conclusion Endostatin has a very good efficacy and safy on non-small cell lung cancer with malignant pleural effusion.It is worthy of clinical study and further clinical observation.